Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Medicine
Published in: BMC Medicine 1/2013

Open Access 01-12-2013 | Research article

Plasminogen activator inhibitor-1 4G/5G polymorphism and retinopathy risk in type 2 diabetes: a meta-analysis

Authors: Tengyue Zhang, Chong Pang, Ningdong Li, Elaine Zhou, Kanxing Zhao

Published in: BMC Medicine | Issue 1/2013

Login to get access

Abstract

Background

Mounting evidence has suggested that plasminogen activator inhibitor-1 (PAI-1) is a candidate for increased risk of diabetic retinopathy. Studies have reported that insertion/deletion polymorphism in the PAI-1 gene may influence the risk of this disease. To comprehensively address this issue, we performed a meta-analysis to evaluate the association of PAI-1 4G/5G polymorphism with diabetic retinopathy in type 2 diabetes.

Methods

Data were retrieved in a systematic manner and analyzed using Review Manager and STATA Statistical Software. Crude odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of associations.

Results

Nine studies with 1, 217 cases and 1, 459 controls were included. Allelic and genotypic comparisons between cases and controls were evaluated. Overall analysis suggests a marginal association of the 4G/5G polymorphism with diabetic retinopathy (for 4G versus 5G: OR 1.13, 95%CI 1.01 to 1.26; for 4G/4G versus 5G/5G: OR 1.30, 95%CI 1.04 to 1.64; for 4G/4G versus 5G/5G + 4G/5G: OR 1.26, 95%CI 1.05 to 1.52). In subgroup analysis by ethnicity, we found an association among the Caucasian population (for 4G versus 5G: OR 1.14, 95% CI 1.00 to 1.30; for 4G/4G versus 5G/5G: OR 1.33, 95%CI 1.02 to 1.74; for 4G/4G versus 5G/5G + 4G/5G: OR 1.41, 95%CI 1.13 to 1.77). When stratified by the average duration of diabetes, patients with diabetes histories longer than 10 years have an elevated susceptibility to diabetic retinopathy than those with shorter histories (for 4G/4G versus 5G/5G: OR 1.47, 95%CI 1.08 to 2.00). We also detected a higher risk in hospital-based studies (for 4G/4G versus 5G/5G+4G/5G: OR 1.27, 95%CI 1.02 to 1.57).

Conclusions

The present meta-analysis suggested that 4G/5G polymorphism in the PAI-1 gene potentially increased the risk of diabetic retinopathy in type 2 diabetes and showed a discrepancy in different ethnicities. A higher susceptibility in patients with longer duration of diabetes (more than 10 years) indicated a gene-environment interaction in determining the risk of diabetic retinopathy.
Appendix
Available only for authorised users
Literature
1.
Hallman DM, Huber JC, Gonzalez VH, Klein BE, Klein R, Hanis CL: Familial aggregation of severity of diabetic retinopathy in Mexican Americans from Starr County, Texas. Diabetes Care. 2005, 28: 1163-1168. 10.2337/diacare.28.5.1163.CrossRefPubMed
2.
Uhlmann K, Kovacs P, Boettcher Y, Hammes HP, Paschke R: Genetics of diabetic retinopathy. Exp Clin Endocrinol Diabetes. 2006, 114: 275-294. 10.1055/s-2006-924260.CrossRefPubMed
3.
Cilensek I, Mankoc S, Globocnik-Petrovic M, Petrovic D: The 4a/4a genotype of the VNTR polymorphism for endothelial nitric oxide synthase (eNOS) gene predicts risk for proliferative diabetic retinopathy in Slovenian patients (Caucasians) with type 2 diabetes mellitus. Mol Biol Rep. 2012, 39: 7061-7067. 10.1007/s11033-012-1537-8.CrossRefPubMed
4.
Petrovic MG, Cilensek I, Petrovic D: Manganese superoxide dismutase gene polymorphism (V16A) is associated with diabetic retinopathy in Slovene (Caucasians) type 2 diabetes patients. Dis Markers. 2008, 24: 59-64.CrossRefPubMed
5.
Churchill AJ, Carter JG, Ramsden C, Turner SJ, Yeung A, Brenchley PE, Ray DW: VEGF polymorphisms are associated with severity of diabetic retinopathy. Invest Ophthalmol Vis Sci. 2008, 49: 3611-3616. 10.1167/iovs.07-1383.CrossRefPubMed
6.
Hudson BI, Stickland MH, Futers TS, Grant PJ: Effects of novel polymorphisms in the RAGE gene on transcriptional regulation and their association with diabetic retinopathy. Diabetes. 2001, 50: 1505-1511. 10.2337/diabetes.50.6.1505.CrossRefPubMed
7.
Richeti F, Noronha RM, Waetge RT, de Vasconcellos JP, de Souza OF, Kneipp B, Assis N, Rocha MN, Calliari LE, Longui CA, Monte O, de Melo MB: Evaluation of AC(n) and C(-106)T polymorphisms of the aldose reductase gene in Brazilian patients with DM1 and susceptibility to diabetic retinopathy. Mol Vis. 2007, 13: 740-745.PubMedPubMedCentral
8.
Maeda M, Yamamoto I, Fukuda M, Nishida M, Fujitsu J, Nonen S, Igarashi T, Motomura T, Inaba M, Fujio Y, Azuma J: MTHFR gene polymorphism as a risk factor for diabetic retinopathy in type 2 diabetic patients without serum creatinine elevation. Diabetes Care. 2003, 26: 547-548. 10.2337/diacare.26.2.547.CrossRefPubMed
9.
Sobrin L, Green T, Sim X, Jensen RA, Tai ES, Tay WT, Wang JJ, Mitchell P, Sandholm N, Liu Y, Hietala K, Iyengar SK, Brooks M, Buraczynska M, van Zuydam N, Smith AV, Gudnason V, Doney AS, Morris AD, Leese GP, Palmer CN, Swaroop A, Taylor HA, Wilson JG, Penman A, Chen CJ, Groop PH, Saw SM, Aung T, Klein BE, et al: Candidate gene association study for diabetic retinopathy in persons with type 2 diabetes: the Candidate gene Association Resource (CARe). Invest Ophthalmol Vis Sci. 2011, 52: 7593-7602. 10.1167/iovs.11-7510.CrossRefPubMedPubMedCentral
10.
Grant MB, Spoerri PE, Player DW, Bush DM, Ellis EA, Caballero S, Robison WG: Plasminogen activator inhibitor (PAI)-1 overexpression in retinal microvessels of PAI-1 transgenic mice. Invest Ophthalmol Vis Sci. 2000, 41: 2296-2302.PubMed
11.
Margaglione M, Cappucci G, d'Addedda M, Colaizzo D, Giuliani N, Vecchione G, Mascolo G, Grandone E, Di Minno G: PAI-1 plasma levels in a general population without clinical evidence of atherosclerosis: relation to environmental and genetic determinants. Arterioscler Thromb Vasc Biol. 1998, 18: 562-567. 10.1161/01.ATV.18.4.562.CrossRefPubMed
12.
Ashton N: Vascular basement membrane changes in diabetic retinopathy. Montgomery lecture, 1973. Br J Ophthalmol. 1974, 58: 344-366. 10.1136/bjo.58.4.344.CrossRefPubMedPubMedCentral
13.
Henry M, Tregouet DA, Alessi MC, Aillaud MF, Visvikis S, Siest G, Tiret L, Juhan-Vague I: Metabolic determinants are much more important than genetic polymorphisms in determining the PAI-1 activity and antigen plasma concentrations: a family study with part of the Stanislas Cohort. Arterioscler Thromb Vasc Biol. 1998, 18: 84-91. 10.1161/01.ATV.18.1.84.CrossRefPubMed
14.
Stegnar M, Uhrin P, Peternel P, Mavri A, Salobir-Pajnic B, Stare J, Binder BR: The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor-1 (PAI-1) gene: relationship to plasma PAI-1 level in venous thromboembolism. Thromb Haemost. 1998, 79: 975-979.PubMed
15.
Eriksson P, Kallin B, van 't Hooft FM, Bavenholm P, Hamsten A: Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA. 1995, 92: 1851-1855. 10.1073/pnas.92.6.1851.CrossRefPubMedPubMedCentral
16.
Santos KG, Tschiedel B, Schneider J, Souto K, Roisenberg I: Diabetic retinopathy in Euro-Brazilian type 2 diabetic patients: relationship with polymorphisms in the aldose reductase, the plasminogen activator inhibitor-1 and the methylenetetrahydrofolate reductase genes. Diabetes Res Clin Pract. 2003, 61: 133-136. 10.1016/S0168-8227(03)00112-8.CrossRefPubMed
17.
Ezzidi I, Mtiraoui N, Chaieb M, Kacem M, Mahjoub T, Almawi WY: Diabetic retinopathy, PAI-1 4G/5G and -844G/A polymorphisms, and changes in circulating PAI-1 levels in Tunisian type 2 diabetes patients. Diabetes Metab. 2009, 35: 214-219. 10.1016/j.diabet.2008.12.002.CrossRefPubMed
18.
Globocnik-Petrovic M, Hawlina M, Peterlin B, Petrovic D: Insertion/deletion plasminogen activator inhibitor 1 and insertion/deletion angiotensin-converting enzyme gene polymorphisms in diabetic retinopathy in type 2 diabetes. Ophthalmologica. 2003, 217: 219-224. 10.1159/000068975.CrossRefPubMed
19.
Nagi DK, McCormack LJ, Mohamed-Ali V, Yudkin JS, Knowler WC, Grant PJ: Diabetic retinopathy, promoter (4G/5G) polymorphism of PAI-1 gene, and PAI-1 activity in Pima Indians with type 2 diabetes. Diabetes Care. 1997, 20: 1304-1309. 10.2337/diacare.20.8.1304.CrossRefPubMed
20.
Zietz B, Buechler C, Drobnik W, Herfarth H, Scholmerich J, Schaffler A: Allelic frequency of the PAI-1 4G/5G promoter polymorphism in patients with type 2 diabetes mellitus and lack of association with PAI-1 plasma levels. Endocr Res. 2004, 30: 443-453. 10.1081/ERC-200035728.CrossRefPubMed
21.
Broch M, Gutierrez C, Aguilar C, Simon I, Richart C, Vendrell J: Genetic variation in promoter (4G/5G) of plasminogen activator inhibitor 1 gene in type 2 diabetes. Absence of relationship with microangiopathy. Diabetes Care. 1998, 21: 463.CrossRefPubMed
22.
Murata M, Maruyama T, Suzuki Y, Saruta T, Ikeda Y: Paraoxonase 1 Gln/Arg polymorphism is associated with the risk of microangiopathy in Type 2 diabetes mellitus. Diabet Med. 2004, 21: 837-844. 10.1111/j.1464-5491.2004.01252.x.CrossRefPubMed
23.
Wong TY, Poon P, Szeto CC, Chan JC, Li PK: Association of plasminogen activator inhibitor-1 4G/4G genotype and type 2 diabetic nephropathy in Chinese patients. Kidney Int. 2000, 57: 632-638. 10.1046/j.1523-1755.2000.00884.x.CrossRefPubMed
24.
Liu SQ, Xue YM, Yang GC, He FY, Zhao XS: Relationship between plasminogen activator inhibitor-1 gene 4G/5G polymorphism and type 2 diabetic nephropathy in Chinese Han patients in Guangdong Province. Di Yi Jun Yi Da Xue Xue Bao. 2004, 24: 904-907.PubMed
25.
Lau J, Ioannidis JP, Schmid CH: Quantitative synthesis in systematic reviews. Ann Intern Med. 1997, 127: 820-826.CrossRefPubMed
26.
DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials. 1986, 7: 177-188. 10.1016/0197-2456(86)90046-2.CrossRefPubMed
27.
Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959, 22: 719-748.PubMed
28.
Begg CB, Mazumdar M: Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994, 50: 1088-1101. 10.2307/2533446.CrossRefPubMed
29.
Egger M, Davey Smith G, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997, 315: 629-634. 10.1136/bmj.315.7109.629.CrossRefPubMedPubMedCentral
30.
Moher D, Liberati A, Tetzlaff J, Altman DG: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009, 339: b2535-10.1136/bmj.b2535.CrossRefPubMedPubMedCentral
31.
Fu YP, Hallman DM, Gonzalez VH, Klein BE, Klein R, Hayes MG, Cox NJ, Bell GI, Hanis CL: Identification of diabetic retinopathy genes through a genome-wide association study among Mexican-Americans from Starr County, Texas. J Ophthalmol. 2010, 2010: 861291.PubMedPubMedCentral
32.
Huang YC, Lin JM, Lin HJ, Chen CC, Chen SY, Tsai CH, Tsai FJ: Genome-wide association study of diabetic retinopathy in a Taiwanese population. Ophthalmology. 2011, 118: 642-648. 10.1016/j.ophtha.2010.07.020.CrossRefPubMed
33.
34.
Niu W, Qi Y: An updated meta-analysis of methylenetetrahydrofolate reductase gene 677C/T polymorphism with diabetic nephropathy and diabetic retinopathy. Diabetes Res Clin Pract. 2012, 95: 110-118. 10.1016/j.diabres.2011.10.009.CrossRefPubMed
35.
Zintzaras E, Chatzoulis DZ, Karabatsas CH, Stefanidis I: The relationship between C677T methylenetetrahydrofolate reductase gene polymorphism and retinopathy in type 2 diabetes: a meta-analysis. J Hum Genet. 2005, 50: 267-275. 10.1007/s10038-005-0250-z.CrossRefPubMed
36.
Zhou JB, Yang JK: Angiotensin-converting enzyme gene polymorphism is associated with proliferative diabetic retinopathy: a meta-analysis. Acta Diabetol. 2010, 47: 187-193.CrossRefPubMed
37.
Fujisawa T, Ikegami H, Kawaguchi Y, Hamada Y, Ueda H, Shintani M, Fukuda M, Ogihara T: Meta-analysis of association of insertion/deletion polymorphism of angiotensin I-converting enzyme gene with diabetic nephropathy and retinopathy. Diabetologia. 1998, 41: 47-53. 10.1007/s001250050865.CrossRefPubMed
38.
Wiwanitkit V: Angiotensin-converting enzyme gene polymorphism is correlated to diabetic retinopathy: a meta-analysis. J Diabetes Complications. 2008, 22: 144-146. 10.1016/j.jdiacomp.2006.09.004.CrossRefPubMed
39.
Zhao T, Zhao J: Association between the -634C/G polymorphisms of the vascular endothelial growth factor and retinopathy in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract. 2010, 90: 45-53. 10.1016/j.diabres.2010.05.029.CrossRefPubMed
40.
Knowler WC, Bennett PH, Bottazzo GF, Doniach D: Islet cell antibodies and diabetes mellitus in Pima Indians. Diabetologia. 1979, 17: 161-164. 10.1007/BF01219743.CrossRefPubMed
41.
Knowler WC, Bennett PH, Hamman RF, Miller M: Diabetes incidence and prevalence in Pima Indians: a 19-fold greater incidence than in Rochester, Minnesota. Am J Epidemiol. 1978, 108: 497-505.PubMed
42.
Hirschhorn JN, Lohmueller K, Byrne E, Hirschhorn K: A comprehensive review of genetic association studies. Genet Med. 2002, 4: 45-61. 10.1097/00125817-200203000-00002.CrossRefPubMed
43.
Schadt EE: Molecular networks as sensors and drivers of common human diseases. Nature. 2009, 461: 218-223. 10.1038/nature08454.CrossRefPubMed
44.
Ioannidis JP, Trikalinos TA, Ntzani EE, Contopoulos-Ioannidis DG: Genetic associations in large versus small studies: an empirical assessment. Lancet. 2003, 361: 567-571. 10.1016/S0140-6736(03)12516-0.CrossRefPubMed
Metadata
Title
Plasminogen activator inhibitor-1 4G/5G polymorphism and retinopathy risk in type 2 diabetes: a meta-analysis
Authors
Tengyue Zhang
Chong Pang
Ningdong Li
Elaine Zhou
Kanxing Zhao
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Medicine / Issue 1/2013
Electronic ISSN: 1741-7015
DOI
https://doi.org/10.1186/1741-7015-11-1

Other articles of this Issue 1/2013

BMC Medicine 1/2013 Go to the issue

Research article

Systematic review of clinical practice guidelines in the diagnosis and management of thyroid nodules and cancer

Guideline

RAMESES publication standards: meta-narrative reviews

Research article

Anti-ribosomal P protein IgG autoantibodies in patients with systemic lupus erythematosus: diagnostic performance and clinical profile

Review

Biologic therapy for autoimmune diseases: an update

Research article

Reporting of analyses from randomized controlled trials with multiple arms: a systematic review

Question and Answer

DSM-5 and ADHD – an interview with Eric Taylor